Paul A. Moore
Chief Scientific OfficerDr. Paul A. Moore, Ph.D., serves as Chief Scientific Officer of Zymeworks Inc. since July 18, 2022. He had been Vice President of Immunology & Cell Biology at MacroGenics, Inc. since April 2008 until July 2022. Dr. Moore has many years of experience working in the biotechnology industry, coordinating efforts focused on the discovery and development of novel biologic based therapies. He began his biotechnology career at Human Genome Sciences, where he directed genomic-based target discovery programs and the preclinical development of various protein and mAb based therapeutics for the treatment of cancer, metabolic, autoimmune and infectious diseases. Prior to joining MacroGenics in 2008, Dr. Moore worked three years at Celera where he managed oncology target validation and mAb development efforts including those directed at cancer stem cells. Dr. Moore obtained his B.Sc. in Biotechnology from the University of Strathclyde, in 1991 he obtained his Ph.D. in Molecular Genetics from the University of Glasgow and completed post-doctoral studies at the Roche Institute of Molecular Biology in Nutley, New Jersey. Dr. Moore brings many years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. He has worked on scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs. Prior to joining MacroGenics, he was Director of Cell Biology at Celera from May 2005 to April 2008, where he oversaw research efforts to develop novel antibody-based therapeutics. Early in his career, he served as Director of Lead Product Development at Human Genome Sciences (HGS), including managing genomic-based target discovery programs that led to the discovery, development, approval and commercialization of Benlysta (belimumab) for the treatment of systemic lupus erythematosus. In 2012, GlaxoSmithKline (GSK). He has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents. Dr. Moore's appointment builds on the new focus on extending its leadership in the biopharmaceutical industry with a renewed organization and expanding pipeline of product candidates with the potential to make a significant difference for patients around the world with difficult-to-treat cancers.
Positions
- Company NameZymeworks Inc.Stock CodeZYMEPositionChief Scientific OfficerColleagues
- KHKenneth H. GalbraithChairman of the Board, CEO & President
- SPScott PlatshonExecutive VP & Chief Business Officer
- KSKristin StaffordExecutive VP & CFO
- MHMark HollywoodExecutive VP & COO
- SMSusan M. MahonyLead Independent Director
- CECarlos E. CampoyIndependent Director
- GAGregory Austin CiongoliIndependent Director
- KMKelvin M. NeuIndependent Director
